Clinical trials
GEP-NET clinical trials
Below are recruiting gep-net clinical trials, each written for real people, not researchers. We’re tracking 12 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05385861Enrolling by invitationPhase 1/Phase 2
ONIVYDE plus carboplatin for advanced gut neuroendocrine cancer
This Phase 1/2 study tests ONIVYDE® (a type of irinotecan drug) combined with carboplatin in people with advanced or metastatic gastroenteropancreatic poorly differentiated neuroendocrine carcinoma. The goal is to see how well the treatment works and how safely it can be given.
Kaohsiung CityAges 20–80 - NCT07319416Recruiting
Ultrasound study for PRRT response in GEP-NET
This trial tests if a special ultrasound can help doctors see how well treatment is working for a type of slow-growing gut or pancreas cancer (GEP-NET). It may help guide your care if you are starting a therapy called PRRT (peptide receptor radionuclide therapy).
Rome, RomeAges 18 years+ - NCT05477576RecruitingPhase 3
Lu-177–treated NET patients: new drug versus standard care
This Phase 3 trial tests RYZ101 versus standard of care in people with inoperable, well-differentiated SSTR-positive GI or pancreas neuroendocrine tumors (NETs) that keep growing after Lu-177 SSA. It may help by improving tumor control after your prior targeted radiation treatment.
Phoenix, ArizonaAges 18 years+ - NCT06356467Recruiting
How tumor and patient factors affect GEP-NEN treatment response
This study looks at how tumor and patient factors affect treatment response in well-differentiated GEP-NENs (neuroendocrine tumors of the digestive system). It may help doctors understand which treatments work best for people like you.
MilanAges 18 years+ - NCT06784752RecruitingPhase 3
Testing a targeted radiation therapy for advanced neuroendocrine tumors
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
Scottsdale, ArizonaAges 12–100 - NCT07165132RecruitingPhase 1
RYZ401 for advanced neuroendocrine tumors
This trial tests an experimental drug called RYZ401 for people with advanced neuroendocrine tumors (NETs) that show a certain marker on scans. The drug is designed to target the tumor cells directly and may be a new option for those who have not had a similar type of targeted radiation therapy.
Iowa City, IowaAges 18 years+ - NCT06256705Recruiting
Study of targeted radiation for neuroendocrine tumors
This study follows people with a type of digestive tract cancer called GEP-NET that has spread and is growing. It uses a special imaging scan to find tumors that absorb a radioactive drug, then treats them with targeted radiation therapy. The goal is to learn more about who benefits most from this treatment.
ClichyAges 18 years+ - NCT06505395RecruitingPhase 2
Octreotide injection for advanced neuroendocrine tumors
This trial is testing an injectable medicine called octreotide for people with advanced neuroendocrine tumors of the digestive system or pancreas. It aims to see if the medicine can help control the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07635316Recruiting
Treatment patterns and outcomes in neuroendocrine tumors
This study examines how doctors treat gastroenteropancreatic neuroendocrine tumors (rare slow-growing cancers of the stomach, pancreas, or intestines) and how patients respond. Researchers will review medical records from 2018–2025 to understand which treatments work best and help improve care for future patients.
East Hanover, New JerseyAges 18–110 - NCT04086485RecruitingPhase 1/Phase 2
Lu-177 dotatate plus olaparib for inoperable neuroendocrine tumors
This study tests whether combining Lu-177 dotatate (a targeted radiation treatment) with olaparib (a targeted pill) can shrink or slow growth of inoperable gastroenteropancreatic neuroendocrine tumors. It’s designed for tumors that show the right “targets” on a special scan and that have started to progress despite standard care.
Bethesda, MarylandAges 18–100 - NCT04837885RecruitingPhase 2
Liver-targeted radioactive drug for GI or pancreas NET liver spread
This study tests a way to deliver a radioactive “somatostatin-type” medicine directly into the liver artery to treat liver-dominant spread of neuroendocrine tumors (NETs). It may help shrink or control liver metastases after standard treatment has not worked enough.
BordeauxAges 18 years+ - NCT07185672RecruitingPhase 3
PRRT with or without chemotherapy for GEP NET
This trial tests whether adding chemotherapy to a standard treatment (PRRT) works better than PRRT alone for people with certain types of digestive tract or pancreatic neuroendocrine tumors. It is for those whose tumors have higher activity on scans or are growing.
Mumbai, MaharashtraAges 18 years+
Hear when a new GEP-NET trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gep-net?
- Yes. Clin2 currently lists 12 recruiting gep-net studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gep-net trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gep-net trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.